Loading organizations...
Injective is a technology company.
Injective has raised $63.0M across 4 funding rounds.
Key people at Injective.
Injective was founded in 2018 by Albert Chon (Co-Founder and CTO).
Injective has raised $63.0M in total across 4 funding rounds.
Injective is a specialized Layer-1 blockchain for decentralized finance (DeFi) applications. It delivers a high-performance, interoperable infrastructure supporting fully decentralized spot and derivatives trading, plus an on-chain orderbook. This platform allows developers to build sophisticated DeFi applications with seamless connectivity.
Co-founded by Eric Chen and Albert Chon in 2018, Injective's origin reflects a belief that traditional finance was exclusive and centralized. Chen, with venture capital experience, and Chon sought to democratize financial market access. This drove them to engineer a blockchain specifically for open, robust financial applications.
Injective primarily serves developers and protocols creating next-generation decentralized financial applications like exchanges and lending platforms. Its vision is to cultivate an open, interoperable global financial paradigm. By providing foundational infrastructure, Injective fosters a fully decentralized, permissionless financial system, enhancing financial autonomy.
Injective was founded in 2018 by Albert Chon (Co-Founder and CTO).
Injective has raised $63.0M in total across 4 funding rounds.
Injective's investors include Kanav Kariya, Brevan Howard Digital, Mark Cuban, BlockTower Capital, Cadenza Ventures, CMS, Hashed, Pantera Capital, QCP Capital, Grasshopper Capital, Symbolic Capital, Axia8 Ventures.
Injective is a Layer 1 blockchain optimized for Web3 finance, providing developers with an open, interoperable network for decentralized finance (DeFi) applications, including secure transactions, near-instant finality, zero gas fees, and high throughput up to 25,000 transactions per second (TPS).[1][3][4][5] It serves DeFi developers, institutions, and users building financial apps like orderbook exchanges, real-world asset (RWA) tokenization, NFTs, and cross-chain solutions, solving key blockchain limitations such as high fees, slow speeds, and poor interoperability with chains like Ethereum and Solana.[1][3][4] Growth momentum includes a $150 million ecosystem fund launched in 2023, over $500 million in iAssets trading volume with 60% weekly market share in on-chain equities, and evolution from a Layer 2 to a full Layer 1 with CosmWasm upgrades.[2][4]
Injective was founded in 2018 by Eric Chen and Albert Chon through Binance Labs' first incubation program, initially launching as a Layer 2 solution for DeFi trading on Ethereum.[1][2][4] Chen and Chon, with backgrounds in blockchain and finance, identified gaps in existing DeFi platforms—rudimentary tools, high costs, and security issues—leading to Injective Labs' creation of a high-performance network.[2][4] Early traction came with a testnet DeFi platform in December 2020, a $10 million funding round in April 2021 backed by Mark Cuban, and a CosmWasm mainnet upgrade in July 2021 for scalable smart contracts, followed by the $150 million ecosystem fund in January 2023 to boost DeFi and infrastructure adoption.[2]
Injective rides the DeFi and Web3 finance wave, capitalizing on surging demand for tokenized RWAs, institutional-grade on-chain trading, and interoperable blockchains amid maturing crypto markets.[3][4] Its timing aligns with Cosmos ecosystem expansion and Ethereum's scaling challenges, offering faster, cheaper alternatives that draw liquidity from fragmented chains.[3] Market forces like regulatory clarity for RWAs and rising institutional adoption favor Injective's high TPS and CLOB, positioning it as infrastructure for global finance while influencing the ecosystem through its $150M fund and 60% on-chain equities dominance.[2][4]
Injective is poised to expand as a DeFi powerhouse, with iAssets and cross-chain bridges driving RWA tokenization growth amid trends like AI-integrated finance and multi-chain liquidity.[3][4] Upcoming developments may include enhanced MultiVM capabilities and deeper institutional integrations, amplifying its role in a $trillion+ tokenized asset market.[4][5] As blockchain finance matures, Injective's speed and zero-fee model will likely solidify its edge, evolving from DeFi innovator to foundational Web3 financial layer—echoing its origins as a Binance-incubated disruptor now scaling global apps.[2][4]
Key people at Injective.
Injective has raised $63.0M across 4 funding rounds. Most recently, it raised $40.0M Other Equity in August 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 9, 2024 | Build on Bitcoin | $1.6M Other Equity | Marguerite de Tavernost | Aave Foundation, Babylon, BlackRock, Centrifuge, Curve, Magic Eden, Mechanism, Ordinals, Rarible, MacLane Wilkison, Vessel Capital |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 10, 2022 | $40.0M Other Equity | Kanav Kariya | Brevan Howard Digital |
| Apr 20, 2021 | $10.0M Other Equity | Mark Cuban, BlockTower Capital, Cadenza Ventures, CMS, Hashed, Pantera Capital, QCP Capital | |
| Apr 1, 2021 | $10.0M Venture Round | Grasshopper Capital, Pantera Capital | |
| Jul 1, 2020 | $3.0M Seed | Pantera Capital | Grasshopper Capital, Symbolic Capital, Axia8 Ventures, Bitlink Capital, Bitscale Capital, BoxOne Ventures, Cabin VC, Innovating Capital, K42, Krypital Group, QCP Soteria |